𝛼SK or SearchD. Western Therapeutics Institute | 4576 FY2026/12 Q2 Follow-Up
SUMMARY
- D. Western Therapeutics Institute, Inc. (DWTI, hereafter the Company) announced its H1 FY2026/12 results after market close on August 13, 2026.
- For TissueBlue , the Company and licensee DORC are currently discussing detailed terms and conditions for extending their agreement in the US, where the patent remains in force.
- SIR believes that if the planned product launches proceed on schedule, expectations for the Company will rise further and be reflected in its share price.
Begin exploring Smartkarma's AI-augmented investing intelligence platform with a complimentary Preview Pass to:
- Unlock research summaries
- Follow top, independent analysts
- Receive personalised alerts
- Access Analytics, Events and more
Join 55,000+ investors, including top global asset managers overseeing $13+ trillion.
Upgrade later to our paid plans for full-access.
or
Already have an account? Sign In Now
Discussions
(Paid Plans Only)
Price Chart(Sign Up to Access)
- D. Western Therapeutics Institute | 4576 FY2026/12 Q2 Follow-Up26 Aug 2026
x